Abstract

In a host of neurodegenerative diseases Tau, a microtubule-associated protein, aggregates into insoluble lesions within neurons. Previous studies have utilized cyanine dyes as Tau aggregation inhibitors in vitro. Herein we utilize cyanine dye 3,3'-diethyl-9-methyl-thiacarbocyanine iodide (C11) to modulate Tau polymerization in two model systems, an organotypic slice culture model derived from Tau transgenic mice and a split green fluorescent protein complementation assay in Tau-expressing cells. In slice cultures, submicromolar concentrations (0.001 microm) of C11 produced a significant reduction of aggregated Tau and a corresponding increase in unpolymerized Tau. In contrast, treatment with a 1 microm dose promoted aggregation of Tau. These results were recapitulated in the complementation assay where administration of 1 microm C11 produced a significant increase in polymerized Tau relative to control, whereas treatment of cells with 0.01 microm C11 resulted in a marked reduction of aggregated Tau. In the organotypic slice cultures, modulation of Tau aggregation was independent of changes in phosphorylation at disease and microtubule binding relevant epitopes for both dosing regimes. Furthermore, treatment with 0.001 microm C11 resulted in a decrease in both total filament mass and number. There was no evidence of apoptosis or loss of synaptic integrity at either dose, however, whereas submicromolar concentrations of C11 did not interfere with microtubule binding, higher doses resulted in a decrease in the levels of microtubule-bound Tau. Overall, a cyanine dye can dissociate aggregated Tau in an ex vivo model of tauopathy with little toxicity and exploration of the use of these type of dyes as therapeutic agents is warranted.

Highlights

  • Abnormal accumulation of aggregated proteins is a common feature of many neurodegenerative disorders including Parkinson, Huntington, and Alzheimer diseases

  • Mutations in the Tau gene are sufficient to cause familial cases of frontotemporal dementia and the disease causing mutations have been shown to alter the propensity for secondary structure and to promote Tau aggregation in vitro (8 –10)

  • N744 is not capable of directly triggering Tau polymerization, it appears capable of increasing the concentration of Tau available for incorporation into fibrils by competitively binding to the negatively charged surfaces presented by polymerization inducers [26]

Read more

Summary

The abbreviations used are

N744, 3-(2-hydroxyethyl)-2-[2-[[3-(2-hydroxyethyl)-5-methoxy-2-benzthiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium; C11, 3,3Ј-diethyl-9-methyl-thiacarbocyanine iodide; 20830 JOURNAL OF BIOLOGICAL CHEMISTRY. Further study revealed that N744 activity is biphasic with optimal inhibition occurring at ϳ4 ␮M [26] This concentration, inhibition is relieved and polymerization levels greater than control samples are observed at higher drug concentrations. GFP fluorescence is altered upon Tau aggregation with higher degrees of polymerization resulting in reduced GFP signal [29] Results show that C11 is capable of significantly reducing levels of aggregated Tau at submicromolar concentrations (0.001 ␮M) with no effects on polymerization with C2. These effects were not dependent on changes in phosphorylation state

EXPERIMENTAL PROCEDURES
RESULTS
C11 Modulates Both Total Filament Mass and Number but Does
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call